Can J Diabetes 42 (2018) S6–S9

Contents lists available at ScienceDirect

Canadian Journal of Diabetes

journal homepage: www.canadianjournalofdiabetes.com

2018 Clinical Practice Guidelines

Methods

Diabetes Canada Clinical Practice Guidelines Expert Committee

Diana Sherifali RN, PhD, CDE, Doreen Rabi MD, MSc, FRCPC, Robyn L. Houlden MD, FRCPC

Process

Following the process used to develop previous Diabetes Canada Clinical Practice Guidelines (1), an Executive Committee, Steering Committee and Expert Committee with broad expertise and geographic representation were assembled. In total, 135 volunteers, from diverse practice settings across the country, including professionals from family medicine, endocrinology, internal medicine, cardiology, neurology, nephrology, infectious disease, urology, psychiatry, psychology, obstetrics, ophthalmology, pediatrics, nursing, dietetics, pharmacy, chiropractic, exercise physiology, and others, participated in the guideline development process.

To further support the principles previously adopted to develop evidence-based recommendations, the current iteration of the guidelines engaged the McMaster Evidence Review and Synthesis Centre to systematically search, review and perform a critical appraisal of the literature. An online database (2) was used to enhance within and across chapter communication and documentation of the review of the literature, and to create guideline "memory" for future iterations of Diabetes Canada Clinical Practice Guidelines. Elements covered by the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument were incorporated into the guideline development process (3).

- Each recommendation had to address a clinically important question related to 1 or more of the following: detection, prognosis, prevention or management of diabetes and its sequelae. Health benefits, risks and side effects of interventions were considered in formulating the recommendations. Patient preferences and values were sought from expert panel members living with diabetes and the literature (where available).
- Whenever possible, each recommendation had to be justified by the strongest clinically relevant, empirical evidence that could be identified; the citation(s) reporting this evidence had to be noted adjacent to the relevant guideline.
- The strength of this evidence, based on prespecified criteria from the epidemiologic literature and other guidelines processes, had to be noted (4–9).
- Each recommendation had to be assigned a grade based on the available evidence, its methodological strength and its applicability to the Canadian population.
- Each recommendation was reviewed by an Independent Methods Review member and had to be approved by the Steering Committee and Executive Committee, with 100% consensus.
- Guidelines based on biological or mechanistic reasoning, expert opinion or consensus had to be explicitly identified and graded as such; harmonization was sought with other Canadian guideline bodies, including the Canadian Cardiovascular Society (CCS), Hypertension Canada and the Canadian Cardiovascular Harmonization of National Guidelines Endeavour (C-CHANGE).

Identifying and Appraising the Evidence

> *"The trials we have comprise islands of evidence, linked by shorter and longer bridges of extrapolation spanning oceans of uncertainty. . . The longer the bridge and the farther we are from an island, the shakier the extrapolation. . .*
> *More good outcomes trials means more islands, shorter bridges and less uncertainty. . .*
> *But there will always be an ocean to span and a bridge to cross." (Hertzel Gerstein, 2015)*

Authors for each chapter were assembled based on their relevant fields of expertise. Each chapter had 1 lead author, 1 or 2 "evidence resource" persons trained or experienced in clinical epidemiology or clinical research methodology, and up to 6 additional authors, as needed. At the outset of the process, committee members from each section of the guidelines attended a workshop on evidence-based practice and guideline development, in order to ensure a consistent approach to the development of recommendations. Committee members identified clinically important questions related to diagnosis, prognosis, prevention and treatment of diabetes and its complications, which were used as a basis for our literature search strategy (outlined below).

Authors were to explicitly define: a) the population to which the question would apply; b) the test, risk factor or intervention being addressed; c) an appropriate reference standard or control population to which the test, intervention or exposure was to be compared; and d) the clinically relevant outcomes being targeted. This information was used to develop specific, clinically relevant questions that were the focus of literature searches. For each question, strategies were developed combining diabetes terms with methodological terms. Two health sciences librarians with expertise in evidence-based practice constructed and peer-reviewed comprehensive searches of the relevant English-language, published, peer-reviewed literature using validated search strategies of electronic databases (MEDLINE, EMBASE, CINAHL, the Cochrane

Conflict of interest statements can be found on page S9.

https://doi.org/10.1016/j.jcjd.2017.10.002

Central Register of Trials, and PsycINFO [where appropriate]). For topics that were covered in the 2013 Clinical Practice Guidelines, the literature searches focused on new evidence published since those guidelines, including literature published in September 2013 or later. For new topics, the search time frame included the literature published since 1990 or earlier where relevant. Updated literature searches were performed at two other intervals throughout the development process.

Once citation duplicates were removed, all references and full-text documents were loaded into DistillerSR (2). Using a priori defined criteria of inclusion and exclusion, all citations were screened at the title and abstract level in duplicate by team members from the evidence centre; full-text screening was completed by a diabetes clinician and methodologist for relevance. All full-text citations and supporting documents were then made available to the chapter authors for review. Authors were asked to review all remaining citations and systematically determine whether the citation would be used for background material, discarded (with justification) or used to support a new or existing recommendation. Each citation that was used to formulate, update or revise a recommendation was critically appraised using standardized tools for treatment, diagnostic or prognostic studies with built-in algorithms to ensure consistent approaches to generating levels of evidence, based on prespecified criteria in Table 1. The level of evidence was then determined by the cited paper's objectives, methodological rigour, susceptibility to bias and generalizability (Table 1). Because they could not be critically appraised, meeting abstracts, narrative review articles, news reports and other sources could not be used to support recommendations. Papers evaluating the cost effectiveness of therapies or diagnostic tests also were not included. Finally, citation flow diagrams depicting the search, review and selection of citations for each chapter, specifically, the number of citations reviewed, removed and requiring new or revised recommendations, are included at the end of each chapter (10).

A number of considerations were made when evaluating the evidence within a given area. For example, people with diabetes are at high risk for several sequelae that are not exclusive to diabetes (e.g. cardiovascular disease, renal failure and erectile dysfunction). As such, some evidence relating to these problems was identified that either excluded, did not report on or did not focus on people with diabetes. Whenever such evidence was identified, a level was assigned using the approach described above. Higher levels were assigned if: a) people with diabetes comprised a predefined subgroup; b) the results in the diabetes subgroup were unlikely to have occurred by chance; and c) the evidence was generated in response to questions that were formulated prior to the analysis of the results. Lower levels (than those indicated in Table 1) were assigned to evidence that did not meet these criteria.

Table 1
Criteria for assigning levels of evidence to the published studies

Level	Criteria
Studies of diagnosis	
Level 1	a) Independent interpretation of test results (without knowledge of the result of the diagnostic or gold standard) b) Independent interpretation of the diagnostic standard (without knowledge of the test result) c) Selection of people suspected (but not known) to have the disorder d) Reproducible description of both the test and diagnostic standard e) At least 50 patients with and 50 patients without the disorder
Level 2	Meets 4 of the Level 1 criteria
Level 3	Meets 3 of the Level 1 criteria
Level 4	Meets 1 or 2 of the Level 1 criteria
Studies of treatment and prevention	
Level 1A	Systematic overview or meta-analysis of high-quality RCTs a) Comprehensive search for evidence b) Authors avoided bias in selecting articles for inclusion c) Authors assessed each article for validity d) Reports clear conclusions that are supported by the data and appropriate analyses OR Appropriately designed RCT with adequate power to answer the question posed by the investigators a) Patients were randomly allocated to treatment groups b) Follow up at least 80% complete c) Patients and investigators were blinded to the treatment* d) Patients were analyzed in the treatment groups to which they were assigned e) The sample size was large enough to detect the outcome of interest
Level 1B	Non-randomized clinical trial or cohort study with indisputable results
Level 2	RCT or systematic overview that does not meet Level 1 criteria
Level 3	Non-randomized clinical trial or cohort study; systematic overview or meta-analysis of level 3 studies
Level 4	Other
Studies of prognosis	
Level 1	a) Inception cohort of patients with the condition of interest, but free of the outcome of interest b) Reproducible inclusion/exclusion criteria c) Follow up of at least 80% of subjects d) Statistical adjustment for extraneous prognostic factors (confounders) e) Reproducible description of outcome measures
Level 2	Meets criterion a) above, plus 3 of the other 4 criteria
Level 3	Meets criterion a) above, plus 2 of the other criteria
Level 4	Meets criterion a) above, plus 1 of the other criteria

* In cases where such blinding was not possible or was impractical (e.g. intensive vs. conventional insulin therapy), the blinding of individuals who assessed and adjudicated study outcomes was felt to be sufficient.
RCT, randomized controlled trial.

Guideline Development

Expert Committee members evaluated the relevant literature, and guidelines were developed and initially reviewed by the Expert Committee. In the absence of new evidence since the publication of the 2013 Clinical Practice Guidelines, recommendations from the 2013 document were not changed.

The studies used to develop and support each recommendation are cited beside the level of evidence. In some cases, key citations that influenced the final recommendation were not assigned the same level of evidence, but rather were of varying levels of evidence. In those circumstances, all relevant studies were cited, regardless of the grading assigned to the recommendation. The final grading depended on the totality of evidence, including the relative strengths of the studies from a methodological perspective and the studies' findings. Studies with conflicting outcomes were considered and cited in the final recommendation and were assigned a grade to reflect the uncertainty signalled by conflicting findings. Further details on the grading process are described below.

Finally, several treatment recommendations were based on evidence generated from the use of 1 therapeutic agent from a given class (e.g. 1 of the "statins"). Whenever evidence relating to 1 or more agents from a recognized class of agents was available, the recommendation was written so as to be relevant to the class, but specifically studied therapeutic agents were identified within the recommendation and/or cited reference(s). Only medications with Health Canada Notice of Compliance granted by September 15, 2017 were included in the recommendations.